Envestnet Asset Management
IMVT icon

Envestnet Asset Management’s Immunovant IMVT Stock Holding History

Envestnet Asset Management’s Portfolio IMVT Stock Details IMVT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-10,799
Closed -$285K – 4267
2024
Q2 		$285K Sell
10,799
-5,701
-35% -$162K ﹤0.01% 3764
2024
Q1 		$533K Buy
16,500
+2,208
+15% +$80.6K ﹤0.01% 3389
2023
Q4 		$602K Sell
14,292
-14,294
-50% -$526K ﹤0.01% 3235
2023
Q3 		$1.1M Buy
+28,586
New +$646K ﹤0.01% 2750

Other funds holding IMVT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
AGM
Alpine Global Management New York $668M AUM 20.22% 1-Year Est. Return

Envestnet Asset Management's IMVT Position: Q3 2024 in Review

Envestnet Asset Management sold out of Immunovant (IMVT) in Q3 2024, closing a stake of 10,799 shares — an estimated $285K sold.

Envestnet Asset Management first reported a position in IMVT in Q3 2023 and held it in 4 quarters. The position peaked at $1.1M in Q3 2023. 181 funds tracked by Wall St. Rank hold IMVT as of Q3 2024.

  • Envestnet Asset Management reported no remaining Immunovant position as of Q3 2024 after selling out during the quarter.
  • Envestnet Asset Management sold 10,799 Immunovant shares in Q3 2024, an estimated $285K.
  • Envestnet Asset Management first reported a position in Immunovant in Q3 2023 and held it in 4 quarters.
  • Envestnet Asset Management's Immunovant position peaked at $1.1M in Q3 2023.
  • 181 funds tracked by Wall St. Rank held Immunovant as of Q3 2024.

Based on Envestnet Asset Management's 13F filing for Q3 2024, filed 7 Nov 2024.